We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+12.05%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.07B
AUM Growth
-$249M
Cap. Flow
-$414M
Cap. Flow %
-13.47%
Top 10 Hldgs %
34.44%
Holding
117
New
6
Increased
34
Reduced
30
Closed
8

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$18.4M
2
ZBIO
Zenas BioPharma
ZBIO
+$15.8M
3
SMMT icon
Summit Therapeutics
SMMT
+$14.5M
4
NUVL
Nuvalent
NUVL
+$14.4M
5
CYTK icon
Cytokinetics
CYTK
+$11.5M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$168M
2
IDXX icon
Idexx Laboratories
IDXX
+$58.2M
3
EVH icon
Evolent Health
EVH
+$51.7M
4
BSX icon
Boston Scientific
BSX
+$28.2M
5
ACHC icon
Acadia Healthcare
ACHC
+$26.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.71%
2 Consumer Staples 1.99%
3 Financials 0.11%
4 Industrials 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRRO icon
101
Korro Bio
KRRO
$199M
$1.19M 0.04%
35,719
– –
KYTX icon
102
Kyverna Therapeutics
KYTX
$480M
$875K 0.03%
178,963
– –
ALLK
103
DELISTED
Allakos
ALLK
$784K 0.03%
1,200,409
– –
VINC
104
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$638K 0.02%
44,586
– –
ACCD
105
DELISTED
Accolade Inc
ACCD
$617K 0.02%
160,217
-2,129,783
-93% -$8.34M
TLPH icon
106
Talphera
TLPH
$73.2M
$271K 0.01%
316,460
– –
NUVB.WS
107
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$13.1K ﹤0.01%
134,028
– –
BPMC
108
CALL
DELISTED
Blueprint Medicines
BPMC
– –
-57,000
Closed -$6.14M
CRL icon
109
Charles River Laboratories
CRL
$13.2B
– –
-60,250
Closed -$12.4M
FULC icon
110
Fulcrum Therapeutics
FULC
$286M
– –
-727,673
Closed -$4.51M
GPCR icon
111
CALL
Structure Therapeutics
GPCR
$3.82B
– –
-65,600
Closed -$2.58M
IDXX icon
112
Idexx Laboratories
IDXX
$46.9B
– –
-119,500
Closed -$58.2M
IMCR icon
113
Immunocore
IMCR
$1.73B
– –
-419,030
Closed -$14.2M
MLYS icon
114
Mineralys Therapeutics
MLYS
$2.41B
– –
-378,932
Closed -$4.43M
OLK
115
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
– –
-500,000
Closed -$12.7M
1 2 3 4
5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Rock Springs Capital Management held 117 positions worth $3.07B, down 7.5% from $3.32B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Rock Springs Capital Management withdrew a net $414M in Q3 2024, closing 8 positions and reducing 30 holdings. Its most notable exit was Idexx Laboratories, an estimated $58.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Rock Springs Capital Management opened a new position in Zenas BioPharma worth $14.9M.

  • Rock Springs Capital Management's largest Q3 2024 buy was Zenas BioPharma: 878,667 shares worth $14.9M.
  • Rock Springs Capital Management added most to Eli Lilly in Q3 2024, an estimated $18.4M increase.
  • Rock Springs Capital Management's biggest Q3 2024 reduction was Blueprint Medicines, cutting an estimated $168M.
  • Rock Springs Capital Management fully exited Idexx Laboratories in Q3 2024, selling an estimated $58.2M.
  • Rock Springs Capital Management's ten largest holdings make up 34% of its $3.07B portfolio in Q3 2024.
  • Rock Springs Capital Management opened 6 new positions and closed 8 in Q3 2024.
  • Rock Springs Capital Management's portfolio value fell 7.5% quarter-over-quarter to $3.07B.

Based on Rock Springs Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.